Daily notes / October 16, 2026

GOODMAN COREY S filed an amended Schedule 13D on Alx Oncology

Written by a model from the facts OQRO holds and checked against them, sentence by sentence of October 16, 2026. Published October 17, 2026. 2 min read.

Tall office buildings around Trinity Church in lower Manhattan seen from above, with the church spire between the towers. — Skyscrapers around Trinity Church, New York, 1905. Photo: Detroit Publishing Company (scan by the New York Public Library), Public domain (scan of a 1905 photograph, New York Public Library Digital Collections). Original

The short answer

GOODMAN COREY S filed a Schedule 13D/A on Oct 16, 2026, reporting 12,927,442 shares, or 9.99% of the class of Alx Oncology (ALXO). The filing is an ownership disclosure and does not state when the shares were bought. Records around the filing include a company Form 8-K, a clinical-trial update and changes in reported market and institutional holdings.

What did GOODMAN COREY S report in the filing?

The SEC Schedule 13D filed by GOODMAN COREY S on Oct 16, 2026 reports 12,927,442 shares, 9.99% of the class of Alx Oncology (ALXO).

A Schedule 13D/A is an ownership filing, not a record of a particular trade. The filing does not say when shares were bought.

How does the filing date relate to company results?

The filing was made 69 days after Alx Oncology's results announcement of Aug 6, 2026, which was reported under 8-K Item 2.02.

That timing describes the sequence of public disclosures. It does not establish what prompted the ownership filing.

What other company filing came around the same time?

Alx Oncology filed a Form 8-K of Oct 15, 2026, one day after, under Items 1.01 and 3.02. OQRO classes the filing as reporting a signed important agreement and the sale of new shares without registering them.

An 8-K item says what the company reported, not what it means for the share price.

What trial and institutional records are available?

ClinicalTrials.gov shows 1 study sponsored by the company updated in the period. The latest, ASPEN-09-03, is a Phase 2 study of evorpacept in combination with trastuzumab and chemotherapy in metastatic HER2-Positi...; its status is recruiting. The study was updated on Sep 25, 2026, with primary completion listed for 2027-12.

In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew were Blackstone Inc. (increased, 766,999 shares) and Driehaus Capital Management LLC (increased, 290,620 shares). The largest position that shrank was Omers Administration Corp (sold out). A 13F is a quarter-end snapshot with no trade date.

What happened to ALXO shares around the filing?

ALXO closed at $0.8947 on Oct 14, 2026, the last session on or before the filing date. From Sep 14, 2026 to Oct 14, 2026, the close moved from $1.93 to $0.8947, a change of −53.5%.

FINRA short interest for ALXO on the settlement date of Sep 30, 2026 was 5,673,137 shares (-9.57% on the previous report), about 3.79 days of average volume. These figures provide context and do not explain the ownership filing or the share-price movement. For related public filings, see Alx Oncology on OQRO.

What this does not tell you?

The Schedule 13D/A does not say when shares were bought. The company's 8-K reports what the company disclosed, not what that disclosure means for the share price.

Share-price moves are listed as context only; the filing does not explain them, and other news can move a price. This article describes public filings and is not investment advice.

Sources

A model wrote this page from the facts OQRO holds; every number, date, name and link in it was checked against those facts before publication, and a text that failed the check was not published. It describes what was filed, not why, and it is not investment advice. How OQRO treats data